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ORIGINAL INVESTIGATIONImpact of Dry Eye on Visual Acuity and Contrast Sensitivity:
Dry Eye Assessment and Management StudyLoretta B. Szczotka-Flynn, OD, PhD, FAAO,1 Maureen G. Maguire, PhD,2* Gui-shuang Ying, PhD,2 Meng C. Lin, OD, PhD, FAAO,3
Vatinee Y. Bunya, MD,2 Reza Dana, MD, MPH,4 and Penny A. Asbell, MD, MBA,5 for the Dry Eye Assessment and
Management (DREAM) Study Research GroupSIGNIFICANCE: Identification of the association of specific signs of dry eye disease with specific visual function
deficits may allow for more targeted approaches to treatment.
PURPOSE: The purpose of this study was to explore the association of dry eye signs and symptoms with visual
acuity (VA) and contrast sensitivity in the Dry Eye Assessment and Management study.
METHODS: Baseline data from participants in the Dry Eye Assessment and Management study were used in this
secondary cross-sectional analysis. Standardized procedures were used to obtain results on the Ocular Surface
Disease Index (OSDI), high-contrast logMAR VA, contrast sensitivity, tear film debris, tear breakup time (TBUT),
corneal fluorescein staining, meibomian gland evaluation, conjunctival lissamine green staining, and Schirmer
test scores. Generalized linear models that included age, refractive error status, and cataract status were used
to assess the association between VA and contrast sensitivity with OSDI score and each dry eye sign. The Hochberg
procedure was used to account for multiple comparisons.
RESULTS: Among 487 participants (974 eyes), worse VA was associated with worse mean score on the OSDI
vision subscale (39.4 for VA 20/32 or worse vs. 32.4 for VA 20/16 or better; adjusted linear trend, P = .02);
scores were not associated with contrast sensitivity. Severe meibomian gland plugging and abnormal secretions
were associated with worse mean log contrast sensitivity (1.48 for severe vs. 1.54 for not plugged [P = .04] and
1.49 for obstructed vs. 1.57 for clear [P = .002], respectively). Longer TBUT was associated with better mean
log contrast sensitivity (1.57 for TBUT >5 seconds and 1.51 for TBUT ≤2 seconds, P < .0001).
CONCLUSIONS:Worse VA rather than worse contrast sensitivity drives vision-related symptoms in dry eye. Greater
tear film instability was associated with worse contrast sensitivity.
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affects quality of life2,7 and is additionally a major risk factor
for a variety of corneal and ocular surface morbidities such as
corneal infection,8,9 thinning,10,11 and contact lens intolerance.12
Disease definitions vary between studies, but studies that define
dry eye based on symptoms report a prevalence ranging from 6.5
to 52.4%, with the majority reporting a prevalence of around
20%.3 The prevalence of disease increases with age, and women
aremore frequently affected.3 Dry eye not only results in decreased
quality of life but also can affect visual function. In a recent natural
history study of dry eye, blurred vision was reported as moderate
to very severe in 58% of dry eye patients compared with only
10.5% in healthy controls.13 Although there are many reports
of decreased visual quality of life and symptoms in dry eye pa-
tients compared with controls,2,7,12 there is little informationsurrounding which specific dry eye signs contribute to diminished
visual function.
Previous studies have assessed corneal irregularity from superfi-
cial punctate keratitis and tear film instability in their relationship
to visual function. Central superficial punctate keratitis in dry eye
has been associated with significant deterioration of visual function
and optical quality measured by functional visual acuity measure-
ments (time-wise change in continuous visual acuity14) and contrast
sensitivity.15–17 Ocular surface damage in the central cornea has
also been associated with increased higher-order aberrations and in-
creased corneal backward light scatter.18 In addition, tear film insta-
bility has been associated with an irregular optical surface affecting
visual function. For example, temporal changes in higher-order
aberrations are associated with the tear film interface in dry eye.19
However, additional studies are needed to understand the relationship387
 prohibited.
FIGURE 1. Flowchart of participants for the analysis cohorts. Exclu-
sions from the full-study group because of different reasons are shown.
Dry Eye Impact on Vision— Szczotka-Flynn et al.between specific dry eye signs and the corresponding effects on
visual function, which in turn will aid clinicians in designing appro-
priate treatment plans for dry eye patients.
Various methods have been used to subjectively assess visual
function in dry eye disease including high- and low-contrast visual
acuity, dynamic visual acuity,14 contrast sensitivity,20 and disability
glare.15,20–22 Because standard high-contrast visual acuity is not
sensitive enough to detect mild ocular disease in other conditions
such as cataract and glaucoma and is known to be variable in dry
eye disease, other measures of visual function are needed. Contrast
sensitivity is a candidate because it is a sensitive indicator of visual
function and ocular disease progression.23–27 However, although
previous studies have shown that contrast sensitivity is a sensitive
measure of the effects of dry eye on visual function,15,17 very few
have assessed which particular clinical signs impact this measure-
ment. To address this knowledge gap, we obtained data from the
Dry Eye Assessment and Management study that has a large, well-
characterized cohort with dry eye disease, including information on
both the standardized assessment of logMAR visual acuity and
contrast sensitivity. In addition, because Sjögren syndrome pa-
tients were included in the study, this subset allowed for an assess-
ment of the effect of aqueous deficiency on bothmeasures. Herein,
we explore the association of dry eye signs and symptoms at
baseline with best-corrected high-contrast logMAR visual acuity and
contrast sensitivity.
METHODS
The Dry Eye Assessment and Management study was a multi-
center, randomized, double-masked clinical trial to evaluate the
effectiveness and safety of supplementation with ω3 fatty acids
in relieving the symptoms of moderate to severe dry eye disease.28
A total of 535 subjects across 27 sites in the United States were
enrolled and followed up for 12months in the primary trial. Eligible
participants were randomized to receive either 3 g of fish-derived
ω3 eicosapentaenoic and docosahexaenoic acids daily (n = 349)
or a placebo containing 5 g of refined olive oil (n = 186). Candi-
dates for the clinical trial were assessed at a screening visit and
an eligibility confirmation visit, which together encompass the
baseline data used in this secondary cross-sectional analysis. The
study protocol was approved by the institutional review board asso-
ciated with each center, carried out under an Investigational New
Drug application for the Food and Drug Administration, conformed
with the tenets of the Declaration of Helsinki, and registered on
ClinicalTrials.gov (NCT02128763). All subjects provided written
informed consent.
Subjects
The trial was designed to include a broad spectrum of symptom-
atic patients with moderate or severe dry eye. Eligibility criteria in-
cluded age ≥18 years, dry eye–related ocular symptoms for at least
6months, use or desire to use artificial tears on average of twomore
times a day during the 2 weeks preceding the screening visit, and
scores on the Ocular Surface Disease Index between 25 and 80,
inclusive, at the screening visit and between 21 and 80, inclusive,
at the eligibility confirmation visit. Scores on the 12-item Ocular
Surface Disease Index range from 0 to 100, where 0 indicates no
ocular discomfort.29 Three subscales of the Ocular Surface Disease
Index (ocular symptoms, vision-related function, and environmental
triggers) also provide scores between 0 and 100. In addition towww.optvissci.com Optom Vis Sci 201
Copyright © American Academy of Optometry. Unauthe Ocular Surface Disease Index, participants completed the
Medical Outcomes Study 36-Item Short FormHealth Survey (scores
range from 0 to 100, with higher scores indicating better health-
related quality of life), although this was not part of the eligibility
assessment. Patients needed to have at least one eye with at least
two of the following four signs: conjunctival lissamine green stain-
ing score ≥1 on a scale of 0 to 6, corneal fluorescein staining
score ≥4 on a scale of 0 to 15, tear film breakup time ≤7 seconds,
and Schirmer test with anesthesia measurement ≥1 to ≤7 mm/
5 min at each of the screening and eligibility visits. Patients with
a history of Sjögren syndrome were included, as were patients with
thyroid disease, rheumatoid arthritis, or inflammatory diseases if
they were otherwise eligible. Medications for dry eye or regular
use of systemicmedications including those known to cause ocular
dryness was allowed if the patient committed to using them for
the next 12 months. However, those who wore contact lens
30 days before the screening visit were ineligible, as were those
who had a history of laser-assisted in situ keratomileusis, ocular
infection, recent ocular surgery, or contraindications to high-dose
ω3 supplementation.
Visual Function Testing
Visual function testing was performed by a Dry Eye Assessment
and Management clinician or technician who had completed a9; Vol 96(6) 388
thorized reproduction of this article is prohibited.
TABLE 1. Characteristics of study participants (n = 487 patients,
974 eyes)
Participant characteristics (n = 487 patients)
Age (y), mean (SD) 57.5 (13.3)
Sex, no. (%)
Female 394 (80.9)
Male 93 (19.1)
Race, no. (%)
White 359 (73.7)
Black 61 (12.5)
Other 67 (13.8)
Ethnicity, no. (%)
Hispanic or Latino 62 (12.7)
Other 425 (87.3)
OSDI score (0–100), mean (SD)
Total 41.8 (15.5)
Vision-related function subscale 34.6 (19.0)
Short Form-36 score (0–100), mean (SD)
Physical health 47.5 (9.7)
Mental health 52.4 (9.4)
Ocular characteristics (n = 974 eyes)
Conjunctival staining score (0–6), mean (SD) 3.0 (1.5)
Corneal staining score (0–15), mean (SD) 3.7 (2.9)
Tear breakup time (s), mean (SD) 3.2 (1.8)
Schirmer test (mm), mean (SD) 9.8 (7.2)
Visual acuity, no. (%)
20/16 or better 239 (24.5)
20/20 251 (25.8)
20/25 282 (29.0)
20/32 153 (15.7)
20/40 49 (5.0)
Mean (SD), in letters 82.5 (6.1)
Log contrast sensitivity score, no. (%)
1.72–1.92 300 (30.8)
1.56–1.68 207 (21.3)
1.44–1.52 237 (24.3)
0.84–1.40 230 (23.6)
Mean (SD) 1.6 (0.2)
Refractive error, no. (%)
Myopia >6 to 11.5 diopters 40 (4.1)
Myopia >3 to ≤6 diopters 88 (9.0)
Myopia >0.5 to ≤3 diopters 277 (28.4)
Emmetropia 325 (33.4)
Hyperopia >0.5 to ≤1.5 diopters 124 (12.7)
Hyperopia >1.5 to 5.5 diopters 120 (12.3)
Mean (SD; diopters) −0.7 (2.7)
TABLE 1. Continued
Ocular characteristics (n = 974 eyes)
Cataract status, no. (%)
No cataract 612 (62.8)
Pseudophakic/aphakic 154 (15.8)
Ongoing cataract 208 (21.4)
OSDI = Ocular Surface Disease Index.
Dry Eye Impact on Vision— Szczotka-Flynn et al.
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testing were performed with correction after manifest refraction
during the baseline visit. Monocular visual acuity testing was per-
formed using the Early Treatment of Diabetic Retinopathy Study
charts and technique at 3.2 m; different charts were used for the
right and left eyes. A light meter was used to ensure that the light
hitting the chart was 189 to 377 lux. The sum of the number of
letters read correctly on each line was recorded. A letter score of
85 corresponds to an approximate Snellen equivalent of 20/20.
Contrast sensitivity was measured with the Mars Letter Contrast
Sensitivity Test following the instructions provided from the man-
ufacturer. Briefly, the chart was illuminated uniformly such that a
light meter measured 189 to 377 lux on the chart. Participants
wore the refractive correction determined by refraction with an
add of +2.00 diopters and an occluder or patch on the untested
eye. The participants' viewing distance to the chart was 50 cm
(20 inches). Different charts were used for the right and left eyes.
Each letter read on the chart was marked as correct or incorrect
until two consecutive letters were read incorrectly by the patient.
The number of letters read on the Mars Contrast Sensitivity Chart
was converted to a log contrast sensitivity value where one addi-
tional letter was associated with an increase of 0.04 units.
Clinical Examination
A Dry Eye Assessment and Management clinician who com-
pleted a certification program for clinical assessment and grading
examined each eye and performed an external examination and
biomicroscopy with a slit lamp. Tear film debris was graded for
each eye as none,mild (present in the inferior tearmeniscus), mod-
erate (present in the inferior tear meniscus and in the tear film over-
lying the cornea), and severe (present in the inferior tear meniscus
and in the tear film overlying the cornea or presence of mucus
strands in the inferior fornix or on the bulbar conjunctiva). At sepa-
rate time points, 2% fluorescein dye and 1% lissamine green dye
were instilled by placing a small pool of dye into a sterile container
using an Eppendorf micropipette and a tip to draw up 5 μL of dye
and placing the volume into the inferior cul-de-sac. After instillation
of fluorescein dye in the right eye, assessment of tear breakup time
was followed sequentially by assessment of corneal fluorescein
staining and meibomian gland evaluation, and after instillation of
lissamine green, staining evaluation of the interpalpebral conjunc-
tiva was conducted; the sequence of testing was repeated for the left
eye. Intraocular pressure was measured for each eye, and Schirmer
test was administered to each eye simultaneously.
Measurement of fluorescein tear breakup time began approxi-
mately 30 seconds after instillation of fluorescein dye. The clini-
cian viewed the cornea through a slit lamp using broad-beam
cobalt blue illumination and a yellow barrier filter. The clinician
instructed the patient to blink and measured the time to the first9; Vol 96(6) 389
thorized reproduction of this article is prohibited.
Dry Eye Impact on Vision— Szczotka-Flynn et al.discontinuity in the tear film with a stopwatch. The measurement
was repeated two more times. The average of the three measure-
ments of tear breakup time per eye was used for analysis. The central
five meibomian glands of the lower lid were assessed after applica-
tion of pressure to the lower eyelid below the lashes using the
Meibomian Gland Evaluator (Johnson & Johnson [previously Tear
Science], Jacksonville, FL). The number of plugged glands was
counted, and secretions were graded as clear liquid oil, mild haze/
cloudy liquid, paste (toothpaste consistency), or obstructed (no
secretion, including capped orifices). Assessment of corneal
staining under the same viewing conditions as those for tear
breakup time began approximately 2 to 3 minutes after the fluo-
rescein dye instillation. The staining of the central cornea and
four surrounding sectors was each scored from 0 (no staining)
to 3 (dense staining). The central corneawas defined as a circular area
encompassing approximately one-fifth of the corneal surface with su-
perior, nasal, inferior, and temporal quadrants extending from the cen-
tral circular zone to the periphery of the cornea, each encompassing
another one-fifth of the corneal surface. Grading of conjunctival stain-
ing began 1 to 2minutes after instillation of lissamine green dye. The
clinician viewed the temporal and nasal conjunctiva through a slit
lamp using white light and graded punctate staining from 0 (no stain-
ing) to 3 in each area. The sum of the scores from all sectors per eye
was used for corneal and conjunctival staining; in addition, only the
central corneal staining score was assessed for association with visual
acuity and contrast sensitivity. Approximately 5 minutes after instilla-
tion of a topical anesthetic, Schirmer test strips were hung onto the
lower conjunctival sac in the temporal one-third of the eyelid.
The patient was instructed to close both eyes. After 5 minutes, as
measured by a stopwatch, the strips were removed, and the length
of wetting of the strip was recorded in millimeters.Statistical Analysis
Participants were excluded from analysis if their visual acuity
scores in at least one eye were worse than 0.44 logMAR (approxi-
mate Snellen equivalent of 20/50) or if there was a history ofTABLE 2. Adjusted mean scores for the OSDI and SF-36 by visual acuity sco
Patients (n)
OSDI (total),
mean (SE)*
Visual acuity in the better eye
20/16 or better 154 41.0 (1.57)
20/20 142 41.7 (1.54)
20/25 139 43.3 (1.54)
20/32 or worse 52 43.2 (2.37)
Linear trend P (adjusted P†) .22 (0.44)
Contrast sensitivity in the better eye
1.72–1.92 187 42.5 (1.42)
1.56–1.68 105 40.3 (1.74)
1.44–1.52 120 43.2 (1.65)
0.84–1.40 77 42.1 (1.98)
Linear trend P (adjusted P†) .86 (0.86)
Boldface indicates statistical significance. *Adjusted by age (continuous), refra
>1.5 diopters,myopia >0.5 to≤3 diopters,myopia >3 to ≤6 diopters, myopia >
outcome measure using the Hochberg procedure. OSDI = Ocular Surface D
www.optvissci.com Optom Vis Sci 201
Copyright © American Academy of Optometry. Unaudiabetic retinopathy in one or both eyes because ocular pathology
other than dry eye would be more likely to be responsible for their
decreased vision. We performed descriptive analyses using mean
(standard deviation) for continuous measures and percentages for
categorical measures. Baseline values for the Ocular Surface Dis-
ease Index were the average of the values from the screening and
eligibility confirmation visits.
We used the generalized linear model to assess the association
between visual acuity and contrast sensitivity with each of the dry
eye symptom measurements (Ocular Surface Disease Index total
score, vision-related subscale score of the Ocular Surface Disease
Index, and Short Form-36 score). In these analyses, visual acuity
or contrast sensitivity was modeled as an independent variable,
and each dry eye symptom score was modeled as a dependent var-
iable, to determine whether subjects with worse vision reported
more symptoms. Because the dry eye symptom measure is person
specific, the visual acuity or contrast sensitivity was based on the
better eye of this specific measurement. To help with the clinical
interpretation and to avoid the strong assumption of linear associa-
tion, the continuous measures (when modeled as independent var-
iables) were categorized into severity levels, and a linear trend
P value was used to test the association.
We used the generalized linear models to evaluate the associa-
tions between each dry eye sign with visual acuity and with contrast
sensitivity. In these models, each dry eye sign was modeled as an
independent variable, and visual acuity or contrast sensitivity was
modeled as the dependent variable, to determine whether eyes
with more severe signs had worse visual acuity scores or contrast
sensitivity. Because measures of dry eye signs, visual acuity, and
contrast sensitivity are all eye specific, these analyses were per-
formed at the eye level, and their intereye correlation was accounted
for by using generalized estimating equations.
Because these associations may differ by the status of Sjögren
syndrome, we tested the interaction of Sjögren syndrome status
with each independent variable. When a statistically significant in-
teraction was found, analyses stratified by Sjögren syndrome status
were performed. Dry Eye Assessment and Management patientsre and contrast sensitivity in the better eye
OSDI vision-related
scale, mean (SE)*
SF-36 physical health
scale, mean (SE)*
SF-36 mental health
scale, mean (SE)*
32.4 (1.92) 47.0 (0.98) 52.6 (0.92)
34.8 (1.89) 46.9 (0.96) 51.7 (0.91)
36.7 (1.88) 47.0 (0.96) 52.0 (0.91)
39.4 (2.91) 47.3 (1.48) 49.6 (1.40)
.01 (0.02) .93 (0.93) .14 (0.14)
34.2 (1.74) 46.9 (0.88) 52.7 (0.84)
32.9 (2.13) 47.7 (1.08) 51.8 (1.03)
38.5 (2.03) 46.4 (1.03) 51.1 (0.98)
35.4 (2.43) 47.2 (1.23) 51.1 (1.17)
.20 (0.20) .90 (0.93) .12 (0.14)
ctive error status (emmetropia, hyperopia >0.5 to ≤1.5 diopters, hyperopia
6 diopters), and cataract status. †Adjust for two comparisons for each of
isease Index; SF-36 = Short Form-36.
9; Vol 96(6) 390
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TABLE 3. Adjusted* mean scores (letters) for visual acuity and log contrast sensitivity by eye-specific signs
Dry eye signs Eyes
VA score (letters),
mean (SE)
Linear trend P
(adjusted P†)
Log contrast sensitivity score,
mean (SE)
Linear trend P
(adjusted P†)
TBUT (s) <.0001 (<.0001) .003 (.02)
>5 114 79.7 (0.62) 1.57 (0.02)
>2 and ≤5 598 82.1 (0.38) 1.58 (0.01)
≤2 262 82.7 (0.49) 1.51 (0.02)
Schirmer test score .98 (.98) .75 (.96)
≤5 304 81.6 (0.45) 1.55 (0.02)
6–10 361 82.4 (0.44) 1.56 (0.02)
11–20 220 82.0 (0.51) 1.57 (0.02)
21–30 66 80.8 (0.77) 1.51 (0.03)
>30 23 82.5 (1.26) 1.52 (0.04)
Tear film debris .003 (.02) .11 (.55)
None 639 81.5 (0.38) 1.55 (0.01)
Mild 269 82.9 (0.49) 1.55 (0.02)
Moderate 66 83.5 (0.94) 1.64 (0.03)
Corneal staining score .70 (.98) .96 (.96)
0–1 266 81.4 (0.47) 1.54 (0.02)
2–3 210 82.5 (0.52) 1.58 (0.02)
4–5 278 82.5 (0.49) 1.57 (0.02)
≥6 218 81.6 (0.55) 1.54 (0.02)
Central corneal staining score .07 (.42) .26 (.78)
0 613 82.0 (0.36) 1.56 (0.01)
1 271 83.1 (0.47) 1.58 (0.02)
2 72 79.8 (0.80) 1.53 (0.03)
3 18 77.3 (1.34) 1.42 (0.06)
Conjunctival staining .82 (.98) .15 (.60)
0–1 136 81.3 (0.56) 1.56 (0.02)
2–3 511 82.5 (0.40) 1.57 (0.01)
≥4 327 81.6 (0.45) 1.54 (0.01)
Meibomian gland .64 (.98) .007 (.04)
None plugged 144 82.1 (0.56) 1.54 (0.02)
Mild 295 82.3 (0.47) 1.59 (0.02)
Moderate 316 81.6 (0.45) 1.57 (0.02)
Severe 219 82.1 (0.56) 1.48 (0.02)
Secretions from meibomian glands .94 (.98) .0003 (.002)
Clear 180 81.9 (0.53) 1.57 (0.02)
Mild haze/cloudiness 387 82.2 (0.44) 1.58 (0.01)
Paste 182 81.9 (0.60) 1.56 (0.02)
Obstructed 225 82.0 (0.55) 1.49 (0.02)
Boldface indicates statistical significance. Log contrast sensitivity score ranges from 0 (100% contrast required to read letters) to 1.92 (1.2% contrast
required to read letters). A score of 1.56means that 2.8% contrast is required to read letters. A VA (score ranges from 0 to 100) score of 80 is equivalent
to 20/25, and a score of 85 is equivalent to 20/20. *Adjusted by age (continuous), refractive error status (emmetropia, hyperopia >0.5 to ≤1.5 diopters,
hyperopia >1.5 diopters, myopia >0.5 to ≤3 diopters, myopia >3 to ≤6 diopters, myopia >6 diopters), and ocular status of cataract. †Adjusted for eight
comparisons of visual acuity scores and for eight comparisons of contrast sensitivity scores using the Hochberg procedure. TBUT = tear breakup time;
VA = visual acuity.
Dry Eye Impact on Vision— Szczotka-Flynn et al.
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Dry Eye Impact on Vision— Szczotka-Flynn et al.were classified as having Sjögren syndrome if an antibody profile
met the 2012 American College of Rheumatology criteria and
had a sum of the Dry Eye Assessment and Management corneal
and conjunctival staining scores of ≥3.
All these statistical models included adjustment of pre-selected
covariates (age, refractive error, and status of cataract). All statisti-
cal analyses were performed in SAS v9.4 (SAS Institute Inc., Cary,
NC). To account for the multiple comparisons from analyzing the
association of multiple factors with dry eye symptoms and from
analyzing multiple dry eyes signs as predictors for visual acuity
and contrast sensitivity, we calculated adjusted P value using
the Hochberg procedure.30 Adjusted P values of <.05 were
considered statistically significant.
RESULTS
Characteristics of Analysis Cohort
Among 535Dry Eye Assessment andManagement participants,
487 participants (974 eyes) were eligible for the analysis after ex-
cluding participants with visual acuity 20/50 or worse in at least
one eye (n = 45 participants), without visual acuity (n = 1 partici-
pant), or with diabetic retinopathy (n = 2 participants; Fig. 1).
Among these remaining 487 eligible subjects, 61 had no Sjögren
syndrome tests or indeterminate Sjögren syndrome status, leaving
45 subjects who had Sjögren syndrome at baseline and 381 subjects
without Sjögren syndrome.
The participant and ocular characteristics of the 487 participants
are displayed in Table 1. The mean (standard deviation) age was 58
(13) years, 81%were female, 74%werewhite, 13%were black, and
13% were Hispanic. The mean (standard deviation) Ocular Surface
Disease Index scores were 42 (16) for the total and 35 (19) for theFIGURE 2. Adjusted mean visual acuity score for signs of dry eye disease asso
tear breakup time (TBUT; right) were associated with better visual acuity. A le
www.optvissci.com Optom Vis Sci 201
Copyright © American Academy of Optometry. Unauvision-related subscale. ThemeanMedical Outcomes Study 36-Item
Short Form Health Survey scores were 48 (9.7) for physical health
and 52 (9.4) for mental health. The mean (standard deviation)
scores of dry eye signs for the cohort are displayed in Table 1.
Association of Visual Acuity and Contrast Sensitivity
with Dry Eye Symptoms
In adjusted analyses (adjusted for age, refractive error, and sta-
tus of cataract), poorer visual acuity was significantly associated
with worse mean Ocular Surface Disease Index vision-related sub-
scale score (adjusted means, 39.4 for visual acuity 20/32 or worse
and 32.4 for visual acuity 20/16 or better; adjusted linear trend,
P = .02). However, visual acuity was not significantly associated
with the mean Ocular Surface Disease Index total score or the
mean Medical Outcomes Study 36-Item Short Form Health Survey
scores (Table 2).
Contrast sensitivity was not significantly associated with mean
Ocular Surface Disease Index scores and mean Medical Outcomes
Study 36-Item Short Form Health Survey scores (Table 2). There
were no significant interactions between Sjögren syndrome and
visual acuity or contrast sensitivity on the association with dry
eye symptoms (all, P ≥ .21).
Association between Dry Eye Signs and Visual Acuity
The results of the adjusted analysis (adjusted for age, refractive
error, and status of cataract) for associations between dry eye signs
and visual acuity are shown in Table 3. Measures of tear film dis-
ruption, including tear film debris and tear breakup time, were
not associated with worse mean visual acuity. Counterintuitively,
increased tear film debris was significantly associated with better
visual acuity score (adjusted mean visual acuity scores, 83.5ciated with visual acuity scores. Greater tear film debris (left) and longer
tter score of 80 is Snellen 20/25.
9; Vol 96(6) 392
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TABLE 4.Multivariable* analysis for visual acuity and contrast sensitivity by signs of dry eye
Dry eye signs
All patients (n = 974 eyes) Patients without Sjögren syndrome (n = 762 eyes)
Eyes (n) Mean (SE) Linear trend P Eyes (n) Mean (SE) Linear trend P
Visual acuity score (letters)
Tear film debris .004 .002
None 639 81.1 (0.40) 498 81.0 (0.43)
Mild 269 82.3 (0.53) 209 82.6 (0.61)
Moderate 66 83.0 (0.91) 55 83.3 (1.01)
TBUT (s) .0009 .0002
>5 114 80.4 (0.67) 84 80.4 (0.73)
>2 and ≤5 598 82.7 (0.47) 478 82.7 (0.53)
≤2 262 83.3 (0.53) 200 83.9 (0.60)
Log contrast sensitivity score
Meibomian gland .01 .003
None plugged 144 1.54 (0.02) 109 1.57 (0.02)
Mild 295 1.58 (0.02) 241 1.59 (0.02)
Moderate 316 1.57 (0.02) 243 1.57 (0.02)
Severe 219 1.48 (0.02) 169 1.49 (0.03)
TBUT (s) .009 .10
>5 114 1.55 (0.02) 200 1.56 (0.03)
>2 and ≤5 598 1.56 (0.01) 478 1.57 (0.02)
≤2 262 1.51 (0.02) 84 1.53 (0.02)
*The model includes age, refractive error status (emmetropia, hyperopia >0.5 to ≤1.5 diopters, hyperopia >1.5 diopters, myopia >0.5 to ≤3 diopters,
myopia >3 to ≤6 diopters, myopia >6 diopters), and ocular status of cataract, tear film debris, and TBUT as predictors. Bold numbers are significant.
TBUT = tear breakup time.
Dry Eye Impact on Vision— Szczotka-Flynn et al.letters for moderate tear film debris and 81.5 letters for none; lin-
ear trend adjusted, P = .02), and longer tear breakup time was
significantly associated with worse visual acuity score (adjusted
mean visual acuity scores, 79.7 letters for tear breakup time
>5 seconds and 82.7 letters for tear breakup time ≤2 seconds;
linear trend, P < .0001; Fig. 2). When the tear film debris and
tear breakup time were considered together in a multivariate
model that was adjusted for age, refractive error status, and cata-
ract status, their association with visual acuity remained statisti-
cally significant for both tear film debris (P = .004) and tear
breakup time (P = .0009; Table 4). Signs of meibomian gland dys-
function (plugged glands and cloudy secretions), conjunctival stain-
ing, and Schirmer test scores were not significantly associated with
visual acuity (all linear trends, P > .64; Table 3).
There was a statistically significant interaction between the
presence of Sjögren syndrome and tear film debris (adjusted,
P = .02) for the association with visual acuity. In an analysis strat-
ified by Sjögren syndrome status (Appendix Table A1, available at
http://links.lww.com/OPX/A404), the mean visual acuity score sig-
nificantly increased with severity of tear film debris (adjusted linear
trend, P = .001) in non–Sjögren syndrome patients; however, in
Sjögren syndrome patients, the mean visual acuity scores did not
show an association with tear film severity (linear trend, P = .07).
Associations between Dry Eye Signs with
Contrast Sensitivity
The adjusted analyses for associations of dry eye signs with con-
trast sensitivity are shown in Table 3. Severe meibomian glandwww.optvissci.com Optom Vis Sci 201
Copyright © American Academy of Optometry. Unauplugging was significantly associated with worse mean log contrast
sensitivity in both the unadjusted and adjusted analyses (adjusted
mean log contrast sensitivity score, 1.48 for severe vs. 1.54 for
none plugged; linear trend adjusted, P = .04). Similarly, the degree
of abnormality in meibomian gland secretions was significantly as-
sociated with worse mean log contrast sensitivity (adjusted mean
log contrast sensitivity scores, 1.49 for obstructed and 1.57 for
clear; linear trend adjusted, P = .002). Longer tear breakup time
was significantly associated with better mean log contrast sensitiv-
ity (adjusted log contrast sensitivity scores, 1.57 for tear breakup
time >5 seconds and 1.51 for tear breakup time ≤2 seconds; linear
trend adjusted,P = .02). Whenmeibomian gland plugging and tear
breakup time were considered together in amultivariatemodel that
was adjusted for age, refractive error status, and cataract status,
the significant association with contrast sensitivity remained for
meibomian gland plugging (P = .01) and tear breakup time
(P = .009; Table 4, Fig. 3). Tear film debris, conjunctival staining,
corneal staining, and Schirmer test score were not significantly as-
sociated with contrast sensitivity (all linear trend adjusted,
P ≥ .55, Table 4).DISCUSSION
Dry eye has a deleterious effect on multiple aspects of visual
function despite normal visual acuity being documented using
standard testing techniques.31 Our data substantiate the finding
that, even among patients with relatively good visual acuity (20/509; Vol 96(6) 393
thorized reproduction of this article is prohibited.
FIGURE 3. Adjusted mean log contrast sensitivity score for signs of dry eye disease associated with contrast sensitivity. Greater meibomian gland
plugging (left) and shorter tear breakup time (TBUT; right) were associated with worse contrast sensitivity.
Dry Eye Impact on Vision— Szczotka-Flynn et al.or better), worse visual acuity corresponded to worse scores on the
Ocular Surface Disease Index vision-related symptoms subscale in
dry eye patients. However, none of the dry eye signs we measured
in the study deleteriously impacted visual acuity. Although subtle
visual acuity changes could be documented based on differences
in tear film debris and tear breakup time, the mean changes were
small (approximately two letters) and not in the direction one would
expect. Alternatively, we found that contrast sensitivity measure-
ments were more sensitive to differences based on dry eye signs re-
lated to tear film stability (tear breakup time and meibomian gland
dysfunction) than conventional visual acuity assessments.
We included evaluation of central corneal fluorescein staining
on vision in the Dry Eye Assessment andManagement participants,
as this has been shown to decrease quality of life in other ocular
surface disease patients and central corneal staining directly im-
pacted functional, dynamic visual acuity in a small dry eye study
of 22 patients.15,32 In addition, Huang and colleagues15 previously
found that, in dry eye patients with punctate epithelial keratopathy,
contrast sensitivity improved after instillation of artificial tears.
However, we were not able to demonstrate an impact on high-
contrast visual acuity or contrast sensitivity with increased central
corneal staining in our dry eye cohort. The Dry Eye Assessment
and Management cohort had relatively low corneal staining scores
overall (mean staining score, 3.6 of 15; Table 1), and we used
static measures of visual acuity and contrast sensitivity rather than
dynamic, which may account for the differences in our findings com-
pared with others.
Using low-contrast optotypes, the measurement of contrast
sensitivity can detect subtle vision changes thatmay not be detected
with standard visual acuity testing. In our study, we detected a
~0.07 difference in log contrast sensitivity in eyes with severewww.optvissci.com Optom Vis Sci 201
Copyright © American Academy of Optometry. Unaumeibomian gland dysfunction or obstructedmeibomian gland secre-
tions comparedwith normal eyes and in eyes with short (≤2 seconds)
tear breakup time compared with eyes with longer (>5 seconds)
times. In other ocular diseases such as glaucoma and age-related
macular degeneration, standard high-contrast visual acuity testing
did not differentiate between milder ocular disease states when
contrast sensitivity did.23–27 For example, in patients with different
stages of glaucoma, mean log contrast sensitivity differed signifi-
cantly between patients with early and moderate visual field de-
fects (1.76 vs. 1.51, respectively).33 In another study, the mean
log contrast sensitivity was 1.62 for healthy subjects aged 22 to
77 years, with significantly lower values in patients with glaucoma
(1.56) or age-related macular degeneration (1.03).34 In addition,
in a study evaluating visual function in recalcitrant neovascular
age-related macular degeneration after switching anti–vascular
endothelial growth factor treatments, mean log contrast sensitiv-
ity improved from 1.32 to 1.40 units, whereas visual acuity remained
stable throughout.35
The findings of improved visual acuity with worse tear film
debris and shorter breakup time were unexpected and counter-
intuitive. These patients may be compensating by blinking more
to distribute the tear film and remove debris that could contribute
to improved vision. Evaluating only the Sjögren syndrome group
can provide us an indication of the impact of aqueous deficiency
on these associations. When we scrutinized only the Sjögren
syndrome group, we found no impact of any ocular signs on high-
contrast visual acuity. That is, the previous associations and trends
of tear film debris and tear breakup time on visual acuity as noted
in the entire cohort were not present in the Sjögren syndrome
group, suggesting that aqueous deficiency does not contribute to
these relationships.9; Vol 96(6) 394
thorized reproduction of this article is prohibited.
Dry Eye Impact on Vision— Szczotka-Flynn et al.Limitations of our study and analyses include having patients
with a limited range of symptoms because patients with mild or
very severe symptoms as measured by the Ocular Surface Dis-
ease Index were excluded. Also, as in most research studies,
visual function was measured as a patient read a chart in an
examination room where blinking may differ from other every-
day activities such as viewing a display screen or reading
printed material.www.optvissci.com Optom Vis Sci 201
Copyright © American Academy of Optometry. UnauIn conclusion, our study found that poorer visual acuity rather
than worse contrast sensitivity drives visual symptoms and com-
plaints in dry eye. However, contrast sensitivity measurements are
more sensitive to worse tear film stability measures (such as tear
breakup time and Meibomian gland plugging) than standard visual
acuity assessments. Future studies that examine how specific ocular
signs affect various measures of visual function would be helpful in
elucidating these relationships and could in turn guide therapies.ARTICLE INFORMATION
Supplemental Digital Content: Appendix Table A1, Ad-
justed mean scores for visual acuity (letters) by tear film
debris stratified by presence or absence of Sjögren syn-
drome are available at http://links.lww.com/OPX/A404.
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